Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00782210




Registration number
NCT00782210
Ethics application status
Date submitted
29/10/2008
Date registered
31/10/2008
Date last updated
9/06/2014

Titles & IDs
Public title
12 / 48 Week Pivotal PFT vs PBO in COPD I
Scientific title
Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Secondary ID [1] 0 0
2008-003647-36
Secondary ID [2] 0 0
1222.11
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Olodaterol (BI1744)
Treatment: Drugs - Olodaterol (BI1744)
Treatment: Drugs - placebo

Experimental: Olodaterol (BI 1744) Low - Low dose inhaled orally once daily from the Respimat inhaler

Experimental: Olodaterol (BI 1744) High - High dose inhaled orally once daily from the Respimat inhaler

Placebo comparator: Placebo - Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler


Treatment: Drugs: Olodaterol (BI1744)
Comparison of low and high doses on efficacy and safety in COPD patients

Treatment: Drugs: Olodaterol (BI1744)
Comparison of low and high doses on efficacy and safety in COPD patients

Treatment: Drugs: placebo
Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)
Timepoint [1] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85
Primary outcome [2] 0 0
Trough FEV1 Response at Day 85 (12 Weeks)
Timepoint [2] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.
Secondary outcome [1] 0 0
Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)
Timepoint [1] 0 0
1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)
Secondary outcome [2] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 1
Timepoint [2] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at day 1
Secondary outcome [3] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks
Timepoint [3] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks
Secondary outcome [4] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks
Timepoint [4] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -1h, -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks
Secondary outcome [5] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks
Timepoint [5] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks
Secondary outcome [6] 0 0
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks
Timepoint [6] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks
Secondary outcome [7] 0 0
Trough FEV1 Response After 2 Weeks
Timepoint [7] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks
Secondary outcome [8] 0 0
Trough FEV1 Response After 6 Weeks
Timepoint [8] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks
Secondary outcome [9] 0 0
Trough FEV1 Response After 18 Weeks
Timepoint [9] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks
Secondary outcome [10] 0 0
Trough FEV1 Response After 24 Weeks
Timepoint [10] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks
Secondary outcome [11] 0 0
Trough FEV1 Response After 32 Weeks
Timepoint [11] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks
Secondary outcome [12] 0 0
Trough FEV1 Response After 40 Weeks
Timepoint [12] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks
Secondary outcome [13] 0 0
Trough FEV1 Response After 48 Weeks
Timepoint [13] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks
Secondary outcome [14] 0 0
Peak FEV1 (0-3h) Response At Day 1
Timepoint [14] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1
Secondary outcome [15] 0 0
Peak FEV1 (0-3h) Response After 2 Weeks
Timepoint [15] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks
Secondary outcome [16] 0 0
Peak FEV1 (0-3h) Response After 6 Weeks
Timepoint [16] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks
Secondary outcome [17] 0 0
Peak FEV1 (0-3h) Response After 12 Weeks
Timepoint [17] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks
Secondary outcome [18] 0 0
Peak FEV1 (0-3h) Response After 24 Weeks
Timepoint [18] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks
Secondary outcome [19] 0 0
Peak FEV1 (0-3h) Response After 48 Weeks
Timepoint [19] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks
Secondary outcome [20] 0 0
Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1
Timepoint [20] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1
Secondary outcome [21] 0 0
Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks
Timepoint [21] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks
Secondary outcome [22] 0 0
FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks
Timepoint [22] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks
Secondary outcome [23] 0 0
FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks
Timepoint [23] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks
Secondary outcome [24] 0 0
FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks
Timepoint [24] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks
Secondary outcome [25] 0 0
FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks
Timepoint [25] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks
Secondary outcome [26] 0 0
Trough FVC Response After 2 Weeks
Timepoint [26] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 2 weeks
Secondary outcome [27] 0 0
Trough FVC Response After 6 Weeks
Timepoint [27] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 6 weeks
Secondary outcome [28] 0 0
Trough FVC Response After 12 Weeks
Timepoint [28] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 12 weeks
Secondary outcome [29] 0 0
Trough FVC Response After 18 Weeks
Timepoint [29] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 18 weeks
Secondary outcome [30] 0 0
Trough FVC Response After 24 Weeks
Timepoint [30] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 24 weeks
Secondary outcome [31] 0 0
Trough FVC Response After 32 Weeks
Timepoint [31] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 32 weeks
Secondary outcome [32] 0 0
Trough FVC Response After 40 Weeks
Timepoint [32] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 40 weeks
Secondary outcome [33] 0 0
Trough FVC Response After 48 Weeks
Timepoint [33] 0 0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug after 48 weeks
Secondary outcome [34] 0 0
FVC Peak (0-3h) Response At Day 1
Timepoint [34] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose at Day 1
Secondary outcome [35] 0 0
FVC Peak (0-3h) Response After 2 Weeks
Timepoint [35] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 2 weeks
Secondary outcome [36] 0 0
FVC Peak (0-3h) Response After 6 Weeks
Timepoint [36] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 6 weeks
Secondary outcome [37] 0 0
FVC Peak (0-3h) Response After 12 Weeks
Timepoint [37] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 12 weeks
Secondary outcome [38] 0 0
FVC Peak (0-3h) Response After 24 Weeks
Timepoint [38] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 24 weeks
Secondary outcome [39] 0 0
FVC Peak (0-3h) Response After 48 Weeks
Timepoint [39] 0 0
1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose after 48 weeks
Secondary outcome [40] 0 0
Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)
Timepoint [40] 0 0
1 hour (h) and 10 minutes (min) prior to dose on first day of randomized treatment (baseline) and -1h and -10 min, 5 min, 15 min, 30 min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h relative to dose at Day 85 (12 weeks)
Secondary outcome [41] 0 0
Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)
Timepoint [41] 0 0
immediately upon arising (before drug administration) from Screening to week 48
Secondary outcome [42] 0 0
Weekly Mean Evening Peak Expiratory Flow Rate (PEF)
Timepoint [42] 0 0
at bedtime from Screening to week 48
Secondary outcome [43] 0 0
Weekly Mean Daytime Rescue Use
Timepoint [43] 0 0
From Screening to week 48
Secondary outcome [44] 0 0
Weekly Mean Nighttime Rescue Use
Timepoint [44] 0 0
From Screening to week 48
Secondary outcome [45] 0 0
Weekly Mean Daily (24h) Rescue Use
Timepoint [45] 0 0
From Screening to week 48
Secondary outcome [46] 0 0
Patient's Global Rating at Week 6
Timepoint [46] 0 0
Week 6 visit
Secondary outcome [47] 0 0
Patient's Global Rating at Week 12
Timepoint [47] 0 0
Week 12 visit
Secondary outcome [48] 0 0
Patient's Global Rating at Week 24
Timepoint [48] 0 0
Week 24 visit
Secondary outcome [49] 0 0
Patient's Global Rating at Week 48
Timepoint [49] 0 0
Week 48 visit
Secondary outcome [50] 0 0
Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Timepoint [50] 0 0
Baseline to end of study at 48 weeks.
Secondary outcome [51] 0 0
Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization
Timepoint [51] 0 0
Baseline to end of study at 48 weeks.
Secondary outcome [52] 0 0
Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Timepoint [52] 0 0
Baseline to end of study at 48 weeks.
Secondary outcome [53] 0 0
Number of COPD Exacerbations
Timepoint [53] 0 0
Baseline to end of study at week 48 visit
Secondary outcome [54] 0 0
Number of COPD Exacerbations Requiring Hospitalization
Timepoint [54] 0 0
Baseline to end of study at week 48 visit
Secondary outcome [55] 0 0
Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Timepoint [55] 0 0
Baseline to end of study at 48 weeks.
Secondary outcome [56] 0 0
Changes in Safety Parameters Related to Treatment
Timepoint [56] 0 0
48 weeks
Secondary outcome [57] 0 0
Change From Baseline in Potassium
Timepoint [57] 0 0
Day 1 and at 12, 24 and 48 weeks

Eligibility
Key inclusion criteria
Inclusion criteria:

* All patients must have a diagnosis of chronic obstructive pulmonary disease
* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 <80% predicted and post-bronchodilator FEV1/FVC <70%
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Patients with a significant disease other than COPD
* Patients with a history of asthma
* Patients with any of the following conditions:

a history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
625
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
1222.11.1143 Boehringer Ingelheim Investigational Site - Concord
Recruitment hospital [2] 0 0
1222.11.1145 Boehringer Ingelheim Investigational Site - Glebe
Recruitment hospital [3] 0 0
1222.11.1144 Boehringer Ingelheim Investigational Site - Westmead
Recruitment hospital [4] 0 0
1222.11.1142 Boehringer Ingelheim Investigational Site - Toorak Gardens
Recruitment hospital [5] 0 0
1222.11.1141 Boehringer Ingelheim Investigational Site - Woodville
Recruitment postcode(s) [1] 0 0
- Concord
Recruitment postcode(s) [2] 0 0
- Glebe
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment postcode(s) [4] 0 0
- Toorak Gardens
Recruitment postcode(s) [5] 0 0
- Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
China
State/province [16] 0 0
Beijing
Country [17] 0 0
China
State/province [17] 0 0
Changsha
Country [18] 0 0
China
State/province [18] 0 0
Chengdu
Country [19] 0 0
China
State/province [19] 0 0
Chongqing
Country [20] 0 0
China
State/province [20] 0 0
Da lian
Country [21] 0 0
China
State/province [21] 0 0
Guangzhou
Country [22] 0 0
China
State/province [22] 0 0
Nanjing
Country [23] 0 0
China
State/province [23] 0 0
Shanghai
Country [24] 0 0
China
State/province [24] 0 0
Shenyang
Country [25] 0 0
China
State/province [25] 0 0
Xi'An
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Germany
State/province [27] 0 0
Erfurt
Country [28] 0 0
Germany
State/province [28] 0 0
Halle
Country [29] 0 0
Germany
State/province [29] 0 0
Kassel
Country [30] 0 0
Germany
State/province [30] 0 0
Oschersleben
Country [31] 0 0
Germany
State/province [31] 0 0
Potsdam
Country [32] 0 0
Germany
State/province [32] 0 0
Weinheim
Country [33] 0 0
New Zealand
State/province [33] 0 0
Hamilton
Country [34] 0 0
New Zealand
State/province [34] 0 0
Otahuhu
Country [35] 0 0
New Zealand
State/province [35] 0 0
Tauranga
Country [36] 0 0
New Zealand
State/province [36] 0 0
Wellington
Country [37] 0 0
Taiwan
State/province [37] 0 0
Changhua
Country [38] 0 0
Taiwan
State/province [38] 0 0
Chia-Yi
Country [39] 0 0
Taiwan
State/province [39] 0 0
Taichung
Country [40] 0 0
Taiwan
State/province [40] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00782210